PF-07265807,Sasanlimab,Axitinib
pfizer
['renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'pfizer']
at asco #gu23, see more about the design of the dose escalation and expansion parts of a phase 1 study assessing an investigative tam kinase inhibitor-based combination regimen in patients with advanced #renalcellcarcinoma tps743 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ